<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Radiance Research Academy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">2534</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url"> http://dx.doi.org/10.31782/IJCRR.2018.10201</article-id><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>VEGF in Renal Cell Carcinoma -__ampersandsignnbsp; A Mini Review&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chandrasekaran</surname><given-names>Deepika</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sundaram</surname><given-names>Sandhya</given-names></name></contrib><contrib contrib-type="author"><name><surname>N.</surname><given-names>Kadhiresan</given-names></name></contrib><contrib contrib-type="author"><name><surname>R.</surname><given-names>Padmavathi</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>26</day><month>10</month><year>2018</year></pub-date><volume>0)</volume><issue/><fpage>1</fpage><lpage>5</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>Angiogenesis is a very important process in the progression of the tumor growth. Vascular endothelial growth factor (VEGF) is a key factor in angiogenesis. The main function is vascular permeability, angiogenesis and endothelial cell growth. An inactivated or impaired tumor suppressor gene Von Hipple Lindaue(VHL) causes accumulation of hypoxia inducible factor (HIF-1A) and leads to increased production of VEGF. The more the expression of VEGF, the worse is the survival and recurrence in many malignancies like Renal Cell Carcinoma. VEGF-targeted therapy plays a major role in various carcinomas involving VEGF pathway for their cancerous growth.__ampersandsignnbsp;&#13;
</p></abstract><kwd-group><kwd> Angiogenesis</kwd><kwd> VEGF</kwd><kwd> Carcinoma</kwd></kwd-group></article-meta></front></article>
